THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 47 filers reported holding THESEUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,163,502 | +185.4% | 131,025 | +60.1% | 0.35% | +203.5% |
| Q4 2022 | $407,658 | -14.2% | 81,859 | -0.0% | 0.12% | -10.2% |
| Q3 2022 | $475,000 | +4.9% | 81,899 | 0.0% | 0.13% | +4.1% |
| Q2 2022 | $453,000 | -51.0% | 81,899 | +2.2% | 0.12% | -49.0% |
| Q1 2022 | $924,000 | -25.2% | 80,124 | -17.8% | 0.24% | -22.5% |
| Q4 2021 | $1,236,000 | – | 97,500 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 4,108,796 | $11,052,661 | 17.63% |
| Omega Fund Management, LLC | 711,479 | $1,913,879 | 1.76% |
| Lynx1 Capital Management LP | 702,415 | $1,889,496 | 1.25% |
| Orbimed Advisors | 17,713,600 | $47,649,584 | 1.01% |
| Nextech Invest Ltd. | 611,310 | $1,644,424 | 0.50% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $6,047,642 | 0.40% |
| Affinity Asset Advisors, LLC | 400,726 | $1,077,953 | 0.30% |
| DENALI ADVISORS LLC | 127,900 | $344,051 | 0.12% |
| Rock Springs Capital Management LP | 437,329 | $1,176,415 | 0.03% |
| Forefront Analytics, LLC | 17,672 | $47,539 | 0.03% |